Search Within

Jan Philipp Bewersdorf

Formats
  1. Meeting Abstract (40)
  2. Journal Article (26)
  3. Review (21)
  4. Research Letter (7)
  5. Correspondence (4)
  6. Editorial (4)
  7. Guidelines (1)
Groups
  1. GME, Medicine (103)
  2. Graduate Medical Education (103)
  3. Hematology-Oncology Fellows (103)
  4. Center for Hematologic Malignancies (60)
  5. Department of Medicine (60)
  6. Hematologic Malignancies, Division of (60)

More Groups

People
  1. Eytan Stein (33)
  2. Aaron Goldberg (20)
  3. Omar Abdel-Wahab (15)
  4. Andriy Derkach (14)
  5. Raajit Rampal (9)
  6. Maximilian Stahl (5)

More People

Years
  1. 2025 (7)
  2. 2024 (26)
  3. 2023 (42)
  4. 2022 (25)
  5. 2021 (3)
Publications
  1. Blood (41)
  2. Leukemia and Lymphoma (7)
  3. Leukemia (6)
  4. Blood Reviews (5)
  5. Journal of Clinical Oncology (4)
  6. American Journal of Hematology (3)

More Publications

Publishers
  1. American Society of Hematology (43)
  2. Nature Publishing Group (8)
  3. Taylor & Francis Group (8)
  4. American Society of Clinical Oncology (5)
  5. Churchill Livingstone (5)
  6. Elsevier Inc. (4)

More Publishers

Results (103)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trial in progress: Venetoclax in combination with ASTX727, an all-oral therapy for chronic myelomonocytic leukemia and other MDS/MPN with excess blasts (VICTORY MDS/MPN): A randomized, phase 2 trial
    Meeting Abstract

    Shallis, R. M.; Blaha, O.; Halene, S.; Mendez, L.; Podoltsev, N. A.; Caldwell, A.; Bewersdorf, J. P.; Little, R. F.; Piekarz, R.; Patnaik, M. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis
    Meeting Abstract

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C. N.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A. T.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M.; Rampal, R. K.; Bose, P.
    Blood (2023)

    Fulltext@MSK | Save
  • Data-driven harmonization of 2022 WHO and ICC classifications of myelodysplastic syndromes/neoplasms (MDS): A study by the International Consortium for MDS (icMDS)
    Meeting Abstract

    Lanino, L.; Ball, S.; Bewersdorf, J. P.; Marchetti, M.; Maggioni, G.; Travaglino, E.; Al Ali, N. H.; Fenaux, P.; Platzbecker, U.; Santini, V.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Validation of the composite complete response (cCR) definitions in the International Working Group (IWG) 2023 criteria in patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) treated with hypomethylating agents (HMA) - A large, multicenter, retrospective analysis from the validate database
    Meeting Abstract

    Bewersdof, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A simple prediction model of outcomes after allogeneic hematopoietic stem cell transplant (HCT) in myelodysplastic syndromes using HCT-comorbidity index, cytogenetic risk, and platelet count
    Meeting Abstract

    Frumm, S. M.; Kim, H. T.; Kelkar, A. H.; Ho, V. T.; Gooptu, M.; Gibson, C. J.; Koreth, J.; Shapiro, R. M.; Romee, R.; Nikiforow, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical implications of TP53 mutations/allelic state in patients (Pts) with myelodysplastic syndromes/neoplasms (MDS) treated with hypomethylating agents (HMA)- a multicenter, retrospective analysis from the VALIDATE database
    Meeting Abstract

    Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Intensive induction chemotherapy (IC) vs hypomethylating agents plus venetoclax (HMA/VEN) in IDH1-or IDH2-mutant newly diagnosed acute myeloid leukemia (AML) - A multicenter cohort study
    Meeting Abstract

    Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Lindsley, R. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • What is the optimal treatment modality in molecularly defined secondary AML? A multicenter cohort study
    Meeting Abstract

    Shimony, S.; Bewersdorf, J. P.; Shallis, R. M.; Liu, Y. W.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Chen, E. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TP53 Y220C mutations in patients with myeloid malignancies
    Meeting Abstract

    Gener-Ricos, G.; Bewersdorf, J. P.; Loghavi, S.; Goldberg, A. D.; Famulare, C.; Issa, G. C.; Borthakur, G.; Kadia, T. M.; Carter, B. Z.; Patel, K. P.; more...
    Blood (2023)

    Fulltext@MSK | Save